Information on this page is provided as a guide and may change. Please verify details directly with the treatment center or other appropriate source before making care decisions.

Institution Logo

UC San Diego Health

Kidney Cancer Program

Primary Address

9400 Campus Point Drive
San Diego, CA, 92037
(858) 657-7876
Appointment Scheduling Phone: (858) 657-7876
Program Website

Satellite Locations

Moores Cancer Center

9400 Campus Point Drive San Diego, CA 92037

McGrath Outpatient Pavilion, UC San Diego Health - Hillcrest

4250 1st Ave San Diego, CA 92103

Key Contacts

Department Chair:
Dr. Manoj Monga
Medical Oncology Lead:
Dr. Rana McKay
Urologic Surgery Lead:
Dr. Aditya Bagrodia
Radiation Oncology Lead:
Dr. Tyler Seibert
Patient Navigator & Appointments:
Call (858) 657-7876
Clinical Trials Contact:
[email protected]
(858) 822-7952

Volume

Metrics reflect this center’s demonstrated experience across key areas of kidney cancer care.

Kidney Cancer Surgery Volume

High

Clear Cell Kidney Cancer Diagnosis Volume

Medium

Non–Clear Cell Kidney Cancer Diagnosis Volume

Very High

About these ratings

Volume and expertise levels are determined using standardized thresholds established by the Kidney Cancer Association and updated annually. Metrics are based on available data and may not reflect the full scope of a center’s capabilities or activity. These metrics are intended to help patients identify centers with demonstrated experience in kidney cancer care.

Types of Services Offered

Clinical Trials End of Life Services Genetic Counseling Infusion Center Integrative Oncology Molecular Testing Multidisciplinary Clinic Oncology Urgent Care Clinic Palliative & Supportive Care Patient Case Discussions / Tumor Boards Precision Medicine Survivorship Clinics Interventional Radiology Medical Oncology Pain Management Palliative Care Pathology Radiation Oncology Radiology Urologic Surgery

Kidney Cancer Types & Expertise

Chromophobe RCC Clear Cell RCC Collecting Duct RCC Papillary RCC Renal Medullary Carcinoma Sarcomatoid Translocation RCC Tuberous Sclerosis–associated RCC Unclassified RCC VHL-associated RCC Bilateral Kidney Tumors Complex Recurrent Cases Cystic Renal Tumors Hereditary Syndromes Kidney Transplant Recipients Solitary Kidney Young Adult (age 18-50)

Special Programs, Recognitions & Outcomes

American College of Surgeons Accredited Cancer Program Government-Funded Research NCI Designated Cancer Center

Research Programs

Clinical Multi-Institutional Collaboration Population-Based Research Lab Translational

Multi-Institutional Collaborations

EDGE Consortium (Endourology Disease Group for Excellence)

SUFU Research Network (Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction)

Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC)

Multi-Institutional Surgical & Outcomes Studies

Patient Resources & Support Services

Fertility Preservation Counseling Financial Navigators Interpreter Services Lodging / Long-Term Housing Lymphedema Therapy Nurse Navigators Nutrition Services / Dietician Occupational Therapy On-site Dispensing / Pharmacy Parking Assistance (valet or concierge) Pastoral / Spiritual Care Patient Navigators Peer Support Options Physical Therapy Psychiatrists / Psychologists Social Workers / Counselors Transportation Service Wellness Center

Insurance Carriers

Accepted

  • Aetna
  • Anthem Blue Cross
  • AXA Assistance USA PPO
  • BCE Emergis
  • Beech Street Capp Care PPO
  • Benefits Panel Service PPO
  • Blue Shield of California
  • Champion Health Plan
  • Cigna
  • CMN Global PPO
  • Covered California Plans
  • Global Excel PPO
  • Health Net
  • Health Smart Preferred PPO/ Interplan PPO
  • Medi-Cal & Medi-Cal Managed Care
  • Medicare
  • Molina Healthcare
  • Claritev PPO (PHCS)
  • National Health Solutions PPO
  • National Provider Network
  • Olympus Managed Healthcare PPO
  • Pacific Foundation for Medical Care PPO
  • TRICARE/TriWest
  • UC-Related plans
  • UnitedHealthcare

Insurance information is provided as a guide and may change. Participation can vary by plan, location, and individual coverage. Please contact the treatment center and your insurance provider directly to confirm that your specific insurance plan is currently accepted and to understand any applicable coverage requirements or costs.

Open Clinical Trials

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended for surgery and has spread from where it first started (primary site) to other places in the body (metastatic). Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses of radiation over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, avelumab, and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib, cabozantinib, and lenvatinib are in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving SABR in combination with standard of care immunotherapy may help shrink or stabilize the cancer in patients with renal cell cancer.

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

The purpose of this study is to evaluate the safety and tolerability of:<br /> <br /> * casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and<br /> * casdatifan monotherapy and casdatifan in combination with cabozantinib or zimberelimab in participants with ccRCC in the dose expansion stage

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Tivozanib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals tumor cells to multiply. This helps stop the spread of tumor cells. Giving pembrolizumab and tivozanib together may work better than pembrolizumab alone in treating patients with RCC.

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

This is a Phase 1b, open-label, multicenter, safety, tolerability and efficacy study of HC-7366 in combination with belzutifan (WELIREG™). This is a multipart study that consists of a HC-7366 monotherapy cohort, a combination dose escalation, and a combination dose expansion. Approximately 80 patients will be enrolled in this study (up to 20 patients will be enrolled into the HC-7366 monotherapy cohort, up to 30 patients into the combination dose escalation, and up to 30 patients into the combination dose expansion). The primary purpose of this study is to determine the maximum tolerated dose of HC-7366 in combination with belzutifan in patients with locally advanced (inoperable) or metastatic RCC with predominantly clear cell histology, irrespective of VHL gene mutation status.

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib in adult patients with confirmed advanced or metastatic clear cell Renal Cell Carcinoma who have experienced progression on or after prior anti-PD-1 or anti-PD-L1 immunotherapy.

ETCTN 10466

A Phase 2 Study of Bevacizumab, Erlotinib, and Aterolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer
Request an Appointment